FORM 3

OrbiMed Capital GP VII LLC

(First)

601 LEXINGTON AVENUE, 54TH FLOOR

(Middle)

(Last)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

By OrbiMed Private Investments VII, LP(3)(4)

By OrbiMed Partners Mater Fund Limited(3)(5)

					n 16(a) of the Securities Exchange of the Investment Company Act of 2					
1. Name and Address of Reporting Person*  ORBIMED ADVISORS LLC		2. Date of Event Requiring Statement (Month/Day/Year)		3. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ ARQT ]						
(Last) (F	First)	(Middle)	01/30/2020		Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)		
(Street) NEW YORK NY 10022					Officer (give title Other (below) below)				6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person	
(City) (S	State)	(Zip)								
			Table I - No	on-Deriva	ative Securities Beneficia	lly Owned				
1. Title of Security	(Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)		
		(e			ve Securities Beneficially ants, options, convertibl		s)			
1. Title of Derivative	Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Securit	ties	4. Conve	ercise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Date Expiration Date		Title	Amount or Number of Shares	Price of Derivative Security		or Indirect (I) (Instr. 5)	
Series B Preferre	d Stock		(1)	(1)	Common Stock	2,825,603	0.0	00	I	By OrbiMed Private Investments VII, LP <sup>(2)(3)</sup>
Series C Preferre	d Stock		(1)	(1)	Common Stock	859,573	0.0	00	I	By OrbiMed Private Investments VII, LP <sup>(3)(4)</sup>
Series C Preferre	d Stock		(1)	(1)	Common Stock	429,786	0.0	00	I	By OrbiMed Partners Mater Fund Limited <sup>(3)(5)</sup>
1. Name and Addres									,	
(Last) 601 LEXINGTO	(First) ON AVENUE	(Middle , 54TH FLOOR	e)							
(Street) NEW YORK	NY	10022	2							
(City)	(State)	(Zip)								
1. Name and Addres										
(Last) 601 LEXINGTO	(First) ON AVENUE	(Middle , 54TH FLOOR	е)							
(Street) NEW YORK	NY	10022	2							
(City)	(State)	(Zip)		_						
1. Name and Addres	ss of Reporting	Person*								

(Street) NEW YORK	NY	10022
(City)	(State)	(Zip)

- 1. Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.
- 2. The securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Capital LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII
- 3. This report on Form 3 is jointly filed by OrbiMed Advisors, OrbiMed Capital GP VII, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- 4. Consists of 859,573 shares of Series C Preferred Stock held by OPI VII. OrbiMed GP VII is the general partner of OPI VII and OrbiMed Advisors is the managing member of OrbiMed GP VII. OrbiMed GP VII. VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Capital is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- 5. Consists of 429,786 shares of Series C Preferred Stock held by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPMF.

## Remarks:

ORBIMED ADVISORS LLC 01/30/2020 By: /s/ Jonathan Silverstein

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.